A human observational case report on weight change and suspected hypersensitivity during 19 weeks of subcutaneous tesamorelin exposure.
Retrospective · Uncontrolled · n=1
Weight Reduction and Suspected Late-Onset Hypersensitivity Following 19 Weeks of Subcutaneous Tesamorelin
RTP Research · 25 October 2026 · Author-supplied manuscript
The paper documents reported weight and clothing-size changes, concurrent therapies, August and September hormonal laboratory results, and injection-site and systemic cutaneous symptoms. Partial improvement approximately 24 hours after withdrawal does not establish causality or a confirmed allergy. The report does not establish tesamorelin-specific weight-loss efficacy or preservation of lean mass.
Tesamorelin initiation is reported as June 14, 2026. May 30 and June 1 precede initiation. Six photographs supplied by the participant, presented chronologically from May 30 to August 15, 2026. Participant-supplied visual body-fat estimates: Before (May 30): 18–22%; After (August 15): 10–13%. Illustrative midpoints: 20% → 11.5%; difference: 8.5 percentage points. These approximate visual ranges are unvalidated estimates, not measurements or a verified change in body composition. Lighting, posture, muscle contraction and camera angle can affect apparent definition.
15 days before initiation · Participant-supplied · Face blurred13 days before initiation · Participant-supplied · Face blurred22 days after initiation · Participant-supplied · Face blurred28 days after initiation · Participant-supplied · Face blurred48 days after initiation · Participant-supplied · Face blurred62 days after initiation · Participant-supplied · Face blurred
Dates follow the participant’s filenames and confirmation and were not independently authenticated. Only a non-generative facial blur was applied; pixels outside the selected facial regions are unchanged. Other identifying features, including tattoos, remain. These photographs do not establish fat loss, lean-mass gain or a tesamorelin-specific effect, with timing based on the participant-reported June 14, 2026 initiation date.